Comparisons
Educational, non-prescriptive side-by-side pages. These are best used to compare mechanisms, evidence maturity, and safety themes—not to choose a protocol.
11 comparisons
Healing / anti-inflammatory
BPC-157 vs TB-500
Experimental healing peptides in context: mechanisms, evidence themes, safety and regulation.
GLP-1 / incretin
Semaglutide vs Tirzepatide
GLP-1 agonist vs dual GIP/GLP-1 agonist: conceptual differences, evidence landscape, and safety themes.
GLP-1 / incretin
Tirzepatide vs Retatrutide
Dual agonist vs investigational triple agonist: mechanism framing and what evidence exists.
GLP-1 / incretin
Semaglutide vs Retatrutide
Approved medicine vs investigational triple agonist: retatrutide's phase 2 weight numbers are larger, but only semaglutide has outcome data — and the head-to-head trial has not reported.
GLP-1 / incretin
Semaglutide vs Liraglutide
Weekly vs daily GLP-1 from the same maker: the albumin-binding chemistry behind the half-life gap, and what SUSTAIN 10 and STEP 8 found head-to-head.
GLP-1 / incretin
CagriSema vs Tirzepatide
Investigational amylin + GLP-1 combination vs approved dual GIP/GLP-1 agonist: why near-identical phase 3 weight numbers are not a head-to-head result.
Healing / anti-inflammatory
BPC-157 vs GHK-Cu
Bundled as healing peptides, but with non-overlapping evidence: rodent-only tendon and gut data versus a small topical cosmetic literature.
Growth hormone axis
MK-677 vs HGH (Somatropin)
Oral ghrelin-receptor secretagogue vs recombinant growth hormone: what the randomized trials found on lean mass, strength, and glucose — plus the regulatory gap.
Growth hormone axis
Ipamorelin vs CJC-1295
Different receptors on one axis: a ghrelin-receptor agonist against a GHRH analog, two abandoned programs, and why the pair is sold as a blend.
Growth hormone axis
CJC-1295 vs Sermorelin
Same GHRH(1-29) backbone, opposite sides of the regulatory line: an approved drug discontinued for commercial reasons vs a compound whose phase 2 ended in a death.
Growth hormone axis
Tesamorelin vs CJC-1295
An FDA-approved GHRH analog next to an abandoned one: phase 3 visceral-fat data that reverses on discontinuation, versus a terminated trial and a unanimous FDA advisory vote.